Skip to Content

Join the 'Prograf' group to help and get support from people like you.

Prograf News

Study Suggests Causes for Lupus' Impact on Immune System

Posted 8 Mar 2016 by

TUESDAY, March 8, 2016 – Scientists have found new clues that help explain what's going wrong in the immune systems of people with lupus – insight they hope will lead to new therapies, or help guide current treatment choices. Lupus has several forms, but the most common is systemic lupus erythematosus (SLE). In SLE, the immune system mistakenly produces antibodies against the body's own tissue. The onslaught can have widespread effects, damaging the skin, joints, heart, lungs, kidneys and brain, according to the Lupus Foundation of America. The disease mostly strikes women, usually starting in their 20s or 30s, the foundation says. In the new study, the researchers found evidence that in people with lupus, some of the immune system's "B cells" mature the wrong way – so that they promote inflammation instead of fighting it. The findings, published online March 8 in the journal ... Read more

Related support groups: Systemic Lupus Erythematosus, Plaquenil, Hydroxychloroquine, Rituxan, Prograf, Rituximab, Lupus Erythematosus, Tacrolimus, Cytoxan, Protopic, Cyclophosphamide, Neosar, Envarsus XR, Cytoxan Lyophilized, Quineprox, Astagraf XL, Plaquenil Sulfate, Hecoria

New Technique Protects Tissue Transplant From Rejection: Study

Posted 13 Aug 2014 by

WEDNESDAY, Aug. 13, 2014 – A new technique for delivering anti-rejection drugs directly to the site of a tissue graft transplant is effective, lasts for months and is safer than drugs that suppress the entire immune system, a new study indicates. After a patient receives a tissue graft transplant – typically on the hand, arm, leg or face – they start taking drugs to prevent their immune system from rejecting and attacking the new tissue. However, this approach can be toxic and leave patients vulnerable to infection. The new approach delivers immunosuppressant drugs directly to the site of the tissue graft transplant, and only when they're needed. A hydrogel (jello-like) material is loaded with an immunosuppressant drug called tacrolimus, and this combination is injected under the skin after transplant surgery. The hydrogel remains inactive until it detects an inflammation/immune ... Read more

Related support groups: Prograf, Tacrolimus, Organ Transplant, Hecoria

Watson Gets Approval for Generic Transplant Drug

Posted 3 Jul 2010 by

From Associated Press (July 2, 2010) MORRISTOWN, N.J. – Watson Pharmaceuticals Inc. said Friday it received approval to sell a generic version of the drug Prograf, which is used to prevent rejection of transplanted organs. The Food and Drug Administration approved Watson's generic version of Prograf, or tacrolimus, in 5-milligram capsules. Watson said it will start shipping the drug immediately. The brand-name version is made by Astellas Pharma, and Watson said U.S. sales totaled $108 million the 12 months ended in May. Prograf is used to suppress the immune system and prevent the rejection of transplanted livers, kidneys, and hearts.   Read more

Related support groups: Prograf

Ask a Question

Further Information

Related Condition Support Groups

Organ Transplant - Rejection Prophylaxis, Organ Transplant - Rejection Reversal

Prograf Patient Information at